YDESNasdaqServices-Medical LaboratoriesFiscal year ends December 31Also trades as YDESW
YD Bio Ltd
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Apr 30, 2026
$6.12+0.20 (+3.38%)
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Quarterly results announced on Form 8-K, Item 2.02
No earnings releases found
YD Bio has not filed an earnings release (Form 8-K, Item 2.02) that we could match to a fiscal quarter.
Press releases
Announcements YD Bio filed with the SEC
INDEX TO UNAUDITED INTERIM CONSOLIDATED FINANCIAL
EX-99.1 to Form 6-K
PRESS RELEASE DATED AUGUST 31, 2026
EX-99.3 to Form 6-K
PRESS RELEASE, DATED AUGUST 11, 2026
EX-99.1 to Form 6-K
PRESS RELEASE, DATED APRIL 30, 2026
EX-99.1 to Form 6-K
PRESS RELEASE, DATED FEBRUARY 25, 2026
EX-99.1 to Form 6-K
PRESS RELEASE, DATED JANUARY 29, 2026
EX-99.1 to Form 6-K
UNAUDITED INTERIM FINANCIAL STATEMENTS OF YD BIOPHARMA LIMITED
EX-99.2 to Form 6-K